Atika Capital Management LLC Has $761,000 Stock Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

Atika Capital Management LLC lowered its holdings in ABIVAX Société Anonyme (NASDAQ:ABVX) by 8.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 103,929 shares of the company’s stock after selling 9,702 shares during the quarter. Atika Capital Management LLC owned 0.16% of ABIVAX Société Anonyme worth $761,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ABVX. JPMorgan Chase & Co. acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth $5,336,000. Franklin Resources Inc. increased its holdings in shares of ABIVAX Société Anonyme by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock worth $10,732,000 after purchasing an additional 141,710 shares during the period. Point72 Asset Management L.P. raised its position in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. abrdn plc lifted its stake in shares of ABIVAX Société Anonyme by 34.1% in the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after buying an additional 107,750 shares during the period. Finally, BNP Paribas Financial Markets grew its position in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ABVX. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $38.00.

ABIVAX Société Anonyme Trading Down 8.1 %

Shares of NASDAQ:ABVX opened at $5.32 on Friday. The business’s fifty day moving average price is $6.77 and its two-hundred day moving average price is $8.14. ABIVAX Société Anonyme has a fifty-two week low of $5.16 and a fifty-two week high of $16.63.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.